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1. Introduction 
Although the expanding prevalence of lifestyle-related diseases such as diabetes mellitus and 
hypertension which ultimately cause renal dysfunction, glomerulonephritis still remains as 
one of the major causes of end-stage renal failure in most countries all over the world. In 
addition to the immunological therapy using corticosteroids and immunosuppressants, 
management of non-immunological risk factors such as hypertension, obesity and disorders of 
glucose and lipid metabolism greatly affect the prognosis of renal function in the treatment of 
patients with glomerulonephritis. Especially, hypertension is a pivotal risk factor for the 
progression of renal injuries and the adequate blood pressure control is a matter of primary 
importance in order to prevent the development of renal dysfunction.  
In this chapter, the importance of blood pressure control is stressed referring the evidence 
thus far, and current topics and future prospects are discussed as to the matters such as 
target blood pressure levels and choices of antihypertensive agents. 
2. Target blood pressure 
Generally, hypertension is diagnosed when the systolic blood pressure is higher than 
140mmHg and/or the diastolic blood pressure is higher than 90mmHg. However, this is an 
arbitrary definition and the linear relation between the blood pressure level and the risk of 
renal dysfunction can be extended even in the normotensive range in epidemiological 
studies. Figure 1 shows the relations of blood pressure level categories and the risk of 
developing end-stage renal failure in 17-year follow-up study of Okinawa prefecture 
residents in Japan (1). Naturally, hypertension increases the risk of renal failure with 
elevating grade of blood pressure levels. Moreover, blood pressure levels lower than 
140/90mmHg but higher than 130/85mmHg, namely the high-normal blood pressure, 
offers a significant risk for future development of renal failure.  
As for the target blood pressure level in the treatment of glomerulonephritis patients, Figure 
2 depicts the outcomes of Modification of Diet in Renal Disease (MDRD) study (2) in which 
the blood pressure control level less than 125/75mmHg brought about slower GFR 
reduction than the level less than 140/90mmHg in subjects with nondiabetic renal diseases 
especially when the proteinuria was prominent. Similarly, Figure 3 plots the annual 
decrease rates of GFR against achieved blood pressure levels in hypertensive subjects with 
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renal diseases (3). In patients whose hypertension was not treated, GFR decreased by more 
than 10mL/min per year. When the blood pressure was lowered to 140/90mmHg, the rate 
of annual GFR decline was reduced by half. However, considering that the physiological 
annual GFR decline with aging is about 1mL/min, the annual GFR decline in 140/90mmHg 
subjects is faster than the natural rate. As compared with this, strict blood pressure lowering 
to 130/85mmHg or 130/80mmHg yielded retardation of GFR decline to a nearly 
physiological level in subjects with renal diseases.  
 
 
Fig. 1. Relationship between the incidence of end-stage renal failure and the blood pressure 
level (1). The incidence of end-stage renal failure is increased not only in hypertensive 
subjects but also in subjects with high-normal blood pressure ranging  
130-139/85-89 mmHg as compared with lower normal blood pressure subjects.  
 
 
Fig. 2. The annual decrease in glomerular filtration rate (GFR) in nondiabetic renal disease 
patients of The Modification of Diet in Renal Disease(MDRD) Study. (2) 
www.intechopen.com
 
Blood Pressure Control in Patients with Glomerulonephritis 457 
Thus, it is suggested that the blood pressure should be lowered below the high-normal level 
in glomerulonephritis patients in order to maximally slow the progression of renal 
dysfunction. Therefore, the American, European and Japanese guidelines for the 
management of hypertension recommend the target blood pressure level of less than 
130/80mmHg in patients with chronic kidney disease (CKD) (4-6).  
 
 
Fig. 3. Relationship between the annual decrease in glomerular filtration rate (GFR) and the 
achieved mean blood pressure level in studies treated hypertensive patients with renal 
diseases (3). The GFR decline rate was suppressed to the level near to the physiological 
decrease with aging in patients whose blood pressure was lowered under 130/85mmHg.  
3. Glomerular hypertension and hyperfiltration 
According to the hyperfiltration theory proposed by Hostteter and Brenner (7,8), increases 
in glomerular capillary pressure, referred to as glomerular hypertension, play an important 
role in the development and the progression of glomerular injuries ultimately resulting in 
glomerular sclerosis and the loss of its nephron. As indicated in Figure 4, not only high 
blood pressure but also increased salt intake and decreased urinary sodium excretion 
resulting in body fluid volume expansion raise intraglomerular capillary pressure and cause 
glomerular hypertension. In addition, the increases in protein intake and glomerular 
efferent arteriolar resistance are also the factors that contribute to the elevation of 
intraglomerular capillary pressure. Long-lasting of sustained glomerular hypertension 
impairs glomerular capillary endothelium and allows filtration of plasma protein molecules, 
followed by widening of mesangial area, obstruction of capillary lumen, hyalinosis of 
glomerular tuft and finally resulting in glomerular sclerosis, abolition of blood flow and 
filtration function. The loss of glomeruli brings about the atrophy of following renal tubules 
and nephrons themselves. Once a certain proportion of nephrons fall into atrophy, the 
intraglomerular capillary pressure and the single nephron filtration glomerular filtration 
rate of remaining glomeruli increase in order to compensate the reduced renal blood flow 
and maintain the glomerular filtration rate, which consequently promote further 
development of glomerular hypertension.  
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Fig. 4. Relations of factors contributing to the increase in intraglomerular capillary pressure 
and progression of glomerular sclerosis.  
In order to stop the progression of this vicious cycle, comprehensive control of factors 
influencing the intraglomerular capillary pressure elevation such as arterial hypertension 
and intakes of salt and protein is needed. As mentioned concerning the target blood 
pressure, strict blood pressure control is important in patients with glomerulonephritis. In 
controlling the blood pressure, it should be kept in mind that reduction of intraglomerular 
capillary pressure as well as systemic arterial pressure is essential in order to achieve 
maximally effective inhibition of glomerular injuries and renal dysfunction. With regard to 
the hemodynamic aspect of renal microcirculation, intraglomerular capillary pressure is 
regulated by the balance between vascular resistances of afferent and efferent glomerular 
arterioles as depicted in Figure 5. A number of neural and humoral factors are known to 
affect the contraction and dilation of glomerular arterioles. Among them, the renin-
angiotensin-aldosterone (RAA) system indicated in Figure 6 is assumed to play a pivotal 
role in the regulation of glomerular hemodynamics. Especially, angiotensin II, a peptide 
exhibiting prominent bioactivities in the RAA system, induce strong contraction of efferent 
rather than afferent glomerular arterioles. In addition, angiotensin II facilitates mesangial 
cell proliferation, increases oxidative stress by activating NAD(P)H oxidase, and induce 
proinflammatory transcription factor NF-B (9,10). These versatile effects of angiotensin II 
also contribute to the progression of renal tissue injuries.  
On the other hand, angiotensin II stimulates the adrenal cortex to secrete aldosterone, a 
major mineralocorticoid, which facilitates renal tubular reabsorption of sodium resulting in 
blood and body fluid volume expansion and blood pressure elevation. Besides this well-
known effect, aldosterone has been shown to promote renal tissue fibrosis and production 
of extracellular matrices such as collagen (9-11). Moreover, aldosterone injures endothelial, 
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epithelial and mesangial cells of glomeruli. In addition, aldosterone, like angiotensin II, 
constricts the efferent arterioles preferably to the afferent arteriole and increase the 
intraglomerular capillary pressure and filtration of plasma protein molecules. Thus, 
aldosterone is also assumed to be a factor exerting detrimental effects to the progression of 
glomerular diseases.  
 
 
Fig. 5. The structure of glomeruli and factors relating to the hemodynamics and hydrauric 
pressure of glomeruli and glomerular arterioles.  
 
 
Fig. 6. Outlines of the renin-angiotensin-aldosterone system and the biological actions 
elicited by its components.  
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Several other hormones and autacoids are known to elicit dilation or contraction of the 
glomerular arterioles. Atrial natriuretic peptide (ANP), produced by the heart, dilates the 
afferent arteriole and preserves renal and glomerular blood flow in the state of heart failure 
(12). This action is supposed to work also in glomerulonephritis patients with reduced renal 
function because the plasma ANP level is increased by body fluid volume increase and 
reduced clearance in the kidney. Vascular endothelium produces vasoactive substances such 
as nitric oxide (NO) and endothelin (ET). NO preferentially dilates and ET preferentially 
contract the afferent arterioles (13,14). NO is supposed to participate in the mechanism of 
increased glomerular filtration in the early stage of diabetic nephropathy, however, the NO 
synthase inhibition has been shown to increase intraglomerular capillary pressure in 
experimental glomerulonephritis (15,16). The pathophysiological implication of ET in the 
glomerular circulation is not well understood.  The kidney has abundant ability to produce 
prostaglandins (PG) from arachidonic acid and PGE2 which facilitates natriuresis and dilates 
the afferent arterioles is the major PG produced in the kidney. As compared with this, PGI2 
produced by vascular endothelium dilates both the afferent and the efferent arterioles (17). 
Nonsteroidal anti-inflammatory drugs such as indomethacin, which inhibit cyclooxygenase 
and PG production, can cause renal dysfunction as the adverse effect. The inflammatory 
process in the pathogenesis of glomerulonephritis is supposed to stimulate PG production in 
the kidney. This possibly increases glomerular and renal blood flow on one hand, however, 
may rather increase intraglomerular pressure on the other hand by preferentially dilating the 
afferent arterioles. However, it has been reported that the long-term administration of PGI2 
analogue mitigated the progression of renal dysfunction without increasing intraglomerular 
capillary pressure in patients with chronic glomerulonephritis (18).  
Taken these together into consideration, it is suggested that the enhancement of RAA system is 
harmful to the glomeruli and the kidney via the nocuous actions of angiotensin II and 
aldosterone. Reductions in renal function generally cause an increase in body fluid volume 
which inhibits plasma renin activity and concentrations of angiotensin II and aldosterone. 
Therefore, the circulating components of RAA system is supposed to be rather suppressed in 
patients with advanced glomerulonephritis. However, the renal and cardiovascular cells have 
been shown to produce components of RAA system such as renin, angiotensin converting 
enzyme (ACE) and aldosterone. In addition, angiotensinogen produced by the liver is 
abundant in plasma. Therefore, it is thought that angiotensin II and aldosterone are locally 
produced in the renal and cardiovascular systems and their concentrations in the tissues may 
be higher than in plasma. And, it is possible that the renal tissue RAA system is rather 
enhanced and contributes to the progression of renal injuries in patients with advanced 
glomerulonephritis although the circulating components of RAA system are suppressed.  
4. Inhibitors of renin-angiotensin-aldosterone system in antihypertensive 
drug therapy for patients with glomerulonephritis 
The precedent sections stressed the importance of strict blood pressure control and the 
implications of RAA system in the management of renal diseases in order to prevent the 
progression of renal dysfunction efficiently and effectively. In this context, inhibitors of 
RAA system such as ACE inhibitors and angiotensin II receptor antagonists (ARB) are 
supposed to provide renoprotective effects in addition to their hypotensive effects by 
inhibiting the detrimental actions of angiotensin II and aldosterone. Especially, these 
inhibitors of RAA system preferentially dilate the efferent arterioles as compared to the 
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afferent arterioles and thereby lower intraglomerular capillary pressure effectively (Figure 
5). Anderson et al. (19) have shown that an ACE inhibitor lowers intraglomerular capillary 
pressure, reduces proteinuria and inhibits the progression of glomerular sclerosis more 
prominently than other antihypertensive drugs in rats with reduced renal mass in which the 
circulating RAA system is thought to be suppressed.  
In human, it is a distinctive feature that the intraglomerular capillary pressure is elevated and 
the GFR is increased at the early stage of diabetic nephropathy. This glomerular hypertension 
facilitates the progression of diabetic nephropathy stages, namely, microalbuminuria, overt 
proteinuria, a GFR reduction, a serum creatinine increase and end-stage renal failure. Taguma 
et al. (20) have first reported that an ACE inhibitor reduces proteinuria in patients with diabetic 
nephropathy, and it is suggested that the suppression of angiotensin II generation brings about 
alleviation of glomerular hypertension and reduce hydrauric transcapillary filtration pressure of 
protein. After that, Lewis et al. (21) performed the multi-center collaborative prospective study 
evaluating the renoprotective effects of an ACE inhibitor in patients with type 1 diabetes 
mellitus presenting overt proteinuria and demonstrated that captopril inhibited the serum 
creatinine increase and the incidence of end-stage renal failure. As well as ACE inhibitors, 
multiple lines of later clinical studies have indicated that ARB are effective in retarding the 
progression of nephropathy at each stage in patients with type 2 diabetes (22-24).  
With regard to the non-diabetic renal disease such as glomerulonephritis, the ACE Inhibition 
in Progressive Renal Insufficiency (AIPRI) study (25) and Ramipril Efficacy in Nephropathy 
(REIN) study (26) showed that ACE inhibitors delay the progression of renal insufficiency in 
European patients with non-diabetic renal disease. Furthermore, African American Study of 
Kidney Disease and Hypertension (AASK) (27) suggested that ACE inhibitors slow renal 
disease progression in African American patients with hypertensive renal disease. Also as for 
the Asian population, we have reported that an ACE inhibitor and an ARB are effective in 
reducing proteinuria and slowing the deterioration of renal function in Japanese patients with 
chronic glomerulonephritis (28,29). Namely, an ACE inhibitor, benazepril, or an ARB, 
valsartan, inhibited the increase in serum creatinine and reduced proteinuria by 30-40% as 
compared with placebo (Figure 7,8). In addition, there is another study reported that an ACE 
inhibitor improved renal outcomes in Chinese patients with advanced stage of non-diabetic 
renal disease whose serum creatinine ranged 3.1 to 5.0mg/dL (30).  
 
 
Fig. 7. Changes in serum creatinine concentrations and urinary protein excretions in 
glomerulonephritis patients given the ACE inhibitor or the placebo (28).  
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Fig. 8. Changes in serum creatinine concentrations and urinary protein excretions in 
glomerulonephritis patients given the angiotensin II receptor blocker (ARB) or the placebo (29). 
As compared with ACE inhibitors and ARB, clinical evidence of other inhibitors of RAA 
system, such as renin inhibitors and aldosterone blockers seems less abundant regarding 
their renoprotecitve effects in patients with glomerulonephritis. In the cascade of RAA 
system indicated in Figure 6, conversion of angiotensinogen to angiotensin I by the 
enzymatic action of renin is assumed to be a rate-limiting step. Therefore, renin inhibitors 
such as aliskiren are thought to be theoretically effective in suppressing the activity of RAA 
system. Aliskiren, alone or in combination with ARB, has been shown to reduce 
albuminuria and proteinuria in patients with diabetic nephropathy (31,32), however, its 
efficacy in patients with glomerulonephritis is to be studied.  
ACE inhibitors are widely used in the treatment of hypertension and renal disease. They 
reduce plasma levels of angiotensin II and aldosterone. However, it has been shown that the 
plasma aldosterone concentration rather increases in a certain portion of patients after 
month of long-term administration and this phenomenon is recognized as aldosterone 
breakthrough. Sato et al. (33) have reported that the long-term ACE inhibitor treatment 
failed to reduce albuminuria in patients with diabetic nephropathy who had developed 
aldosterone breakthrough, however, the albuminuria significantly reduced after adding 
spironolactone, an aldosterone blocker. Although spironolactone can cause adverse effects 
by its partially estrogenic actions such as gynecomastia and menstrual disorder which 
sometimes hamper the continuation of administration, eplerenone, a newly developed 
aldosterone blocker, is much more specific to the mineralocorticoid receptor and almost free 
from such estrogenic side effects. There is paucity of clinical evidence as to the effects of 
aldosterone blockers in glomerulonephritis patients, however, the use of an aldosterone 
blocker in addition to an ACE inhibitor or an ARB would be expected to exhibit protective 
effects against the progressions of glomerular injuries and renal dysfunction.  
5. Calcium channel blockers in antihypertensive drug therapy for patients 
with glomerulonephritis 
Although the guidelines for hypertension management recommend strict blood pressure 
control in order to prevent organ injuries and cardiovascular diseases, the target blood 
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pressure is generally achieved only in less than a half of hypertensive patients under 
treatment. In terms of lowering blood pressure, the hypotensive effect of CCB, directly 
dilating vascular smooth muscle, is consistently reliable in various conditions including 
glomerulonephritis patients. Therefore, the addition of CCB to RAA system inhibitors is 
expected to bring about effective blood pressure reduction with few chances to cause 
impeding adverse effects.  
Ca channels residing in the plasma membrane of cells are composed five subunits; 1, 2, , 
 and . Among them, the 1 subunit conforming Ca2+ ion pathway has isoforms of L, N, 
P/Q, R and T. There are three isoforms of 1 subunit, L, N and T in the cardiovascular 
tissues, and Table 1 shows their distributions, functions and pharmacological blockers. 
Dihydropyridine (DHP) CCB, which are generally used as hypertensive drugs, blocks the L-
type Ca channels existing in the arterial smooth muscle. With regard to the glomerular 
arterioles, because the afferent but not the efferent arterioles have the L-type channels, DHP 
CCB generally preferentially dilate the afferent arterioles. Therefore, it is supposed that the 
reduction in intraglomerular capillary pressure may not be so prominent as compared with 
the reduction in systemic arterial pressure. In this respect, the N-type and the T-type 
channels exist both in the afferent and the efferent arterioles and the blockers of these Ca 
channels are assumed to dilate both glomerular arterioles. This property is expected to 
contribute to the reduction in intraglomerular capillary pressure. Indeed, the N-type CCB, 
cilnidipine, and the T-type CCB such as efonidipine and azelnidipine have been shown to 
reduce proteinuria significantly in patients with glomerulonephritis as compared with L-
type CCB (Figure 9), suggesting these CCB are effective in alleviating glomerular 
hypertension (34-36).  
 
 
Fig. 9. The glomerular filtration rate (GFR) and the urinary excretions of protein in 
glomerulonephritis patients given the L-type Ca channel blocker (CCB), amlodipine,  
or the L- and T-type CCB, efonidipine (35).  
As listed in Table 1, T-type Ca channels exist also in the adrenal and the in vitro experiments 
using cultured adrenal cells have shown that the T-type CCB suppress the expression of 
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aldosterone synthase gene (CYP11B2) and production of aldosterone (37,38). In harmony with 
this, clinical studies in healthy subjects and hypertensive patients have shown that the acute or 
the chronic administrations of T-type CCB lower plasma aldosterone levels (39,40). We have 
compared the effects of L- and T-type CCB efonidipine and L-type CCB amlodipine in patients 
with glomerulonephritis and observed that efonidipine reduces plasma aldosterone 
concentration as compared with amlodipine while the plasma angiotensin II concentrations 
were comparable (Figure 10)(35). It is mentioned in the previous section of this chapter that 
aldosterone is supposed to promote the progression of glomerular injuries and the aldosterone 
blocker can reduce albuminuria. Considering that the mechanism of aldosterone suppression 
by T-type CCB is different from those by ACE inhibitors, ARB and aldosterone blockers, this 
property of T-type CCB would be expected to provide an additive benefit, when combined 
with the RAA system inhibitors, against the progression of renal dysfunction in the 
antihypertensive treatment of glomerulonephritis patients.  
 
Ca channel Tissue distribution Function Blocker 
L-type 
vascular smooth muscle 
intestinal smooth muscle
vasocontraction 
intestinal contraction 
nifedipine 
nicardipine 
nitrendipine 
amlodipine 
etc. 
N-type 
brain
nerve end
facilitation of signal 
transmission
cilnidipine 
T-type 
vascular smooth muscle 
cardiac muscle 
adrenal 
vasocontraction 
stimulation of excitement 
conduction 
aldosterone secretion 
manidipine 
efonidipine 
benidipine 
azelnidipine 
mibefradil 
Table 1. Subtypes of Ca channel and their locations, functions and blockers. 
 
 
Fig. 10. The plasma concentrations of angiotensin II and aldosterone in glomerulonephritis 
patients given the L-type Ca channel blocker (CCB), amlodipine, or the L- and T-type CCB, 
efonidipine (35). 
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6. Summary and conclusions 
Strict blood pressure control over 24 hours is of primary importance in preventing 
progression of renal injuries and deterioration of renal function in patients with glomerular 
diseases. In addition, it is important to lower not only systemic blood pressure but also 
intraglomerular capillary pressure in order to protect glomeruli from sclerosis because the 
increase in intraglomerular capillary pressure, glomerular hypertension, causes filtration of 
albuminuria and proteinuria which are dose-dependently related to the progression of renal 
injuries. Therefore, the antihypertensive therapy in patients with glomerulonephritis should 
aim not only the normalization of blood pressure but also the reduction of proteinuria and 
albuminuria. In order to lower intraglomerular capillary pressure, inhibitors of RAA system 
such as ACE inhibitors and ARB are effective as antihypertensive drugs because angiotensin 
II greatly contribute to the contraction of the efferent arterioles of glomeruli. In addition, 
interests are attracted as to the usefulness aldosterone receptor blockers and renin inhibitors 
as novel agents protecting the kidney. CCB are potent hypotensive agents, however, they 
rather dilate the afferent arterioles and may not be so effective as RAA system inhibitors in 
lowering intraglomerular capillary pressure. In this respect, some dihydropyridine CCB 
which block not only L-type Ca channel but also N- or T-type Ca channel have been shown 
to dilate efferent arterioles in addition to dilating afferent arterioles and are expected to be 
beneficial to protect glomeruli as well as lowering blood pressure effectively. 
Prognosis of renal function in glomerulonephritis may be largely dependent on the nature 
of its pathohistological diagnosis and the therapeutic effects of immunosuppressive agents. 
In addition to these, efforts to lessen and minimize risk factors for renal injuries should be 
continuously made in order to inhibit the deterioration of renal function. Such efforts would 
be expected to contribute to inhibit not only the development of renal failure but also the 
incidence of cardiovascular diseases and to improve the prognosis of glomerulonephritis 
patients. Among the various risk factors for real injuries hypertension has great influence 
and the adequate blood pressure control is  a pivotally important issue.  
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